Mycrodose Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Early Stage VC
- (Cancelled)
- Investors
-
9
Mycrodose General Information
Description
Developer of advanced drug delivery systems designed to treat cancer-related conditions, mental health disorders, and cognitive degenerative diseases. The company specializes in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases, enabling patients to get advanced drugs to treat them fast through a safe and scalable approach.
Contact Information
Website
www.mycrodosethera.comCorporate Office
- 5940 Pacific Mesa Court
- Suite 209
- San Diego, CA 92121
- United States
Corporate Office
- 5940 Pacific Mesa Court
- Suite 209
- San Diego, CA 92121
- United States
Mycrodose Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 21-Oct-2021 | Cancelled | Startup | |||
| 1. Seed Round | 07-Sep-2021 | Completed | Startup |
Mycrodose Patents
Mycrodose Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230026731-A1 | Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent | Inactive | 31-Mar-2021 | ||
| WO-2022212789-A1 | Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent | Inactive | 31-Mar-2021 | ||
| WO-2022221072-A1 | Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent | Inactive | 31-Mar-2021 | A61K31/4045 |
Mycrodose Signals
Mycrodose Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ambria Capital | Venture Capital | Minority | ||
| Four Acres Capital | Venture Capital | Minority | ||
| H.E.N.R.Y Collective | Venture Capital | Minority | ||
| K2 & Associates Investment Management | Hedge Fund | |||
| Negev Capital | Venture Capital | Minority |
Mycrodose Investments (1)
Mycrodose’s most recent deal was a Joint Venture with Kelai Pharmaceutical. The deal was made on 01-Jan-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kelai Pharmaceutical | 01-Jan-2021 | Joint Venture | Drug Discovery |
Mycrodose FAQs
-
When was Mycrodose founded?
Mycrodose was founded in 2020.
-
Where is Mycrodose headquartered?
Mycrodose is headquartered in San Diego, CA.
-
What is the size of Mycrodose?
Mycrodose has 12 total employees.
-
What industry is Mycrodose in?
Mycrodose’s primary industry is Drug Discovery.
-
Is Mycrodose a private or public company?
Mycrodose is a Private company.
-
What is Mycrodose’s current revenue?
The current revenue for Mycrodose is .
-
How much funding has Mycrodose raised over time?
Mycrodose has raised $1.5M.
-
Who are Mycrodose’s investors?
Ambria Capital, Four Acres Capital, H.E.N.R.Y Collective, K2 & Associates Investment Management, and Negev Capital are 5 of 9 investors who have invested in Mycrodose.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process